Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

TCGA-50-5044-01A-21R-1858-07

— · cohortA1

21fcebac-b305-516c-aa75-bbf66d2fa822

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortA1
subtype
cohortA1
age_years
72

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.570
  • COAGULATION+0.450
  • ANGIOGENESIS+0.440
  • PANCREAS_BETA_CELLS+0.390
  • INTERFERON_ALPHA_RESPONSE+0.370
  • ALLOGRAFT_REJECTION+0.350
  • APICAL_JUNCTION+0.330
  • INTERFERON_GAMMA_RESPONSE+0.300
  • COMPLEMENT+0.280
  • MYOGENESIS+0.280

Top 10 suppressed

  • PROTEIN_SECRETION-0.390
  • MITOTIC_SPINDLE-0.310
  • CHOLESTEROL_HOMEOSTASIS-0.280
  • G2M_CHECKPOINT-0.250
  • E2F_TARGETS-0.240
  • FATTY_ACID_METABOLISM-0.220
  • PEROXISOME-0.220
  • UNFOLDED_PROTEIN_RESPONSE-0.180
  • DNA_REPAIR-0.130
  • HEME_METABOLISM-0.130

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-FD-A5BT-01A-11R-A26T-07
bladder-landscape@3
——0.889
2R304
bladder-landscape@3
——0.857
3TCGA-E9-A1NF-01A-11R-A14D-07
breast-umap@18
—C0.850
4MDT-AP-2584
medullo-epn-umap@date-based
MedMedulloblastoma0.845
5MDT-AP-0484
medullo-epn-umap@date-based
MedMedulloblastoma0.840
6ERR2598321
medullo-epn-umap@date-based
fetalfetal0.840
720120155.TNBC
breast-umap@18
—D0.836
8TCGA-77-8131-01A-11R-2247-07
lung-landscapes@6
—cohortSQ10.836
9MDT-AP-0567
medullo-epn-umap@date-based
MedMedulloblastoma0.834
10TCGA-99-8028-01A-11R-2241-07
lung-landscapes@6
—cohortMD20.832

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.570Inavolisib— uncovered
COAGULATION0.450Binimetinib— uncovered
ANGIOGENESIS0.440Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.390Cobimetinib— uncovered
INTERFERON_ALPHA_RESPONSE0.370Inavolisib— uncovered
ALLOGRAFT_REJECTION0.350Idelalisib— uncovered
APICAL_JUNCTION0.330Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.300Idelalisib— uncovered
COMPLEMENT0.280Inavolisib— uncovered
MYOGENESIS0.280Inavolisib— uncovered
HYPOXIA0.260Idelalisib— uncovered
KRAS_SIGNALING_UP0.260Inavolisib— uncovered
P53_PATHWAY0.240Idelalisib— uncovered
APOPTOSIS0.220Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.210Inavolisib— uncovered
HEDGEHOG_SIGNALING0.200Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.190Inavolisib— uncovered
IL2_STAT5_SIGNALING0.180Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.180Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.170Idelalisib— uncovered